Results 31 to 40 of about 42,544 (264)
HBeAg-induced CD33+ cells suppress T-cell activation. [PDF]
, 2019 (A) PBMCs from healthy donors were untreated (control) or treated with rHBeAg (0.5 μg/ml) for 5 days. CD33+ cells were then isolated and incubated with autologous Pan T cells in the presence of human T-activator CD3/CD28 beads for 3 days (middle and ...
Jiming Zhang (381471) +12 more
core +1 more source
Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission [PDF]
, 2014 A significant portion of HBeAg-negative chronic hepatitis B patients have persistently normal serum alanine aminotransferase levels (PNALT). We thus investigated host genetic variants and virological features in HBeAg-negative hepatitis B carriers ...
陳定信 ;高嘉宏 ;蘇東弘 ;賴明陽 ;劉俊人 ;陳培哲 +1 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2019 Hepatitis B e antigen (HBeAg) has been considered to cause immunotolerance to hepatitis B virus (HBV) in newborn infants after fetal HBeAg exposure.
Hongyu Huang +7 more
doaj +1 more source
Mathematical investigation of HBeAg seroclearance
Mathematical Biosciences and Engineering, 2019 Spontaneous or drug-induced loss of hepatitis B e antigen is considered a beneficial event in the disease progression of chronic hepatitis B virus infections. Mathematical models of within-host interactions are proposed; which provide insight into hepatitis B e antibody formation, its influence on hepatitis B e antigen seroclearance, and reversion of ...
Sarah Kadelka, Stanca M Ciupe
openaire +4 more sources
Treating Immune-tolerant Hepatitis B [PDF]
, 2017 Hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma worldwide. On the basis of virus-host interactions, the natural history of HBV carriers can be divided into four chronological phases.
Tseng, T-C;Kao, J-H, 高嘉宏
core +1 more source
Di-san junyi daxue xuebao, 2022 Objective To evaluate the predictive efficacy of serum pregenomic RNA (pgRNA) level in HBeAg clearance for chronic hepatitis B (CHB) patients treated with polyethylene glycol interferon alfa (PEG-IFN-α).
LIU Zhongwei +4 more
doaj +1 more source
Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas [PDF]
, 1996 This paper uses meta-analysis of published data and a deterministic mathematical model of hepatitis B virus (HBV) transmission to describe the patterns of HBV infection in high endemicity areas.
Edmunds, W. John +5 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2019 Recently, we showed that infants with or without fetal hepatitis B e antigen (HBeAg) exposure had comparable antibody response to hepatitis B vaccination and proposed that fetal HBeAg exposure appears to not induce immunotolerance to HBV.
Hongyu Huang +7 more
doaj +1 more source
CHRONIC HEPATITIS B VIRUS INFECTION IN PREGNANCY: STRATEGIES OF ANTIVIRAL THERAPY
Alʹmanah Kliničeskoj Mediciny, 2016 Treatment of chronic hepatitis B during pregnancy is an extremely complicated issue. Despite implementation of immune prophylaxis, a significant proportion of babies born by mothers with high viral load are infected by hepatitis B virus.
P. O. Bogomolov +5 more
doaj +1 more source
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. [PDF]
, 2010 The main objectives of this study were to define the occurrence and levels of hepatitis B virus (HBV) DNA in asymptomatic HBV carriers, cirrhosis patients and hepatocellular carcinoma (HCC) cases from The Gambia, and to evaluate the risk for cirrhosis or
Whittle, H +23 more
core +1 more source